Jan 19th, 2026
Today’s Late-Breaking Science
The Thursday Main Event will present the results from six Late-Breaking Science trials and the Thomas Willis Award Lecture.
Thursday’s Main Event | 11 a.m.-12:30 p.m. | Main Event 2
- Factor XIa Inhibition With Asundexian in Acute Non-Cardioembolic Stroke or High-Risk Transient Ischemic Attack: Primary Results of the OCEANIC-STROKE Trial
- Tenecteplase for Acute Nonlarge Vessel Occlusion at 4.5-24 Hours
- Intravenous Tenecteplase Plus Endovascular Thrombectomy vs. Endovascular Thrombectomy Alone on 4.5 to 24 Hours After Stroke Due to Basilar Artery Occlusion: A Multicenter Randomized Controlled, Clinical Trial (ATTENTION LATE)
- Endovascular Treatment With or Without Preceding Intravenous Tenecteplase in Patients With Late-Window Acute Ischemic Stroke Due to Middle Cerebral Artery Occlusion (TNK-PLUS): A Multicenter Prospective Open-Label, Blinded Endpoint, Phase 3, Randomized Controlled Trial
- The EMBOLISE Study: Embolization of the Middle Meningeal Artery With ONYXTM Liquid Embolic System in the Treatment of Subacute and Chronic Subdural Hematoma
- Tirofiban for Branch Atheromatous Disease-Related Stroke: A Randomized Double-Blind, Placebo-Controlled Trial
